Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging

Kidney International

Volumn 76, Issue SUPPL. 114, 2009, Pages

  Vlassara, Helen ^a   Torreggiani, Massimo ^b   Post, James B ^a   Zheng, Feng ^a   Uribarri, Jaime ^a   Striker, Gary E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Advanced glycation end products; Age related kidney function; Dietary oxidants; Inflammation; Kidney disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE; CREATININE; PYRIDOXAMINE; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; OXIDIZING AGENT;

AGING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COGNITION; CREATININE BLOOD LEVEL; DETOXIFICATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET; HUMAN; INFLAMMATION; KIDNEY FUNCTION; MICROALBUMINURIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ADULT; ANIMAL; CHRONIC KIDNEY FAILURE; COOKING; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGING; ANIMALS; COGNITION; COOKERY; DIABETIC NEPHROPATHIES; DIET; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; KIDNEY; KIDNEY FAILURE, CHRONIC; OXIDANTS; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 77449125773     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.401     Document Type: Review

References (70)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
2. Kilhovd BK, Juutilainen A, Lehto S et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 2007; 50: 1409-1417. (Pubitemid 46879016)
3. Himmelfarb J, McMonagle E. Manifestations of oxidant stress in uremia. Blood Purif 2001; 19: 200-205.
4. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000; 58: 2571-2578.
5. Uribarri J, Cai W, Peppa M et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007; 62: 427-433. (Pubitemid 47065712)
6. Ruggiero C, Metter EJ, Melenovsky V et al. High basal metabolic rate is a risk factor for mortality: the Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci 2008; 63: 698-706.
7. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-285. (Pubitemid 15087125)
8. Rowe JW, Andres R, Tobin JD et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155-163.
9. Pizzarelli F, Lauretani F, Bandinelli S et al. Predictivity of survival according to different equations for estimating renal function in community-dwelling elderly subjects. Nephrol Dial Transplant 2009; 24: 1197-1205.
10. Färbom P, Wahlstrand B, Almgren P et al. Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: the Nordic diltiazem study. Hypertension 2008; 52: 115-122.
11. Cai W, He JC, Zhu L et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol 2007; 170: 1893-1902. (Pubitemid 47339263)
12. Cai W, He JC, Zhu L et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 2008; 173: 327-336.
13. Himmelfarb J. Acute kidney injury in the elderly: problems and prospects. Semin Nephrol 2009; in press.
14. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489-1494.
15. Lassnigg A, Schmidlin D, Mouhieddine M et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 2004; 15: 1597-1605. (Pubitemid 38679685)
16. Kellum JA, Hoste EA. Acute kidney injury: epidemiology and assessment. Scand J Clin Lab Invest Suppl 2008; 241: 6-11. (Pubitemid 351883670)
17. Feest TG, Round A, Hamad S. Incidence of severe acute renal failure in adults: results of a community based study. BMJ 1993; 306: 481-483. (Pubitemid 23053155)
18. Pascual J, Liaño F, Ortuño J. The elderly patient with acute renal failure. J Am Soc Nephrol 1995; 6: 144-153.
19. Schmitt R, Cantley LG. The impact of aging on kidney repair. Am J Physiol Renal Physiol 2008; 294: F1265-F1272.
20. Schmitt R, Coca S, Kanbay M et al. Recovery of kidney function after acute kidney injury in the elderly: a systematic review and meta-analysis. Am J Kidney Dis 2008; 52: 262-271. (Pubitemid 351978133)
21. Ishani A, Xue JL, Himmelfarb J et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20: 223-228.
22. Eggers P. The aging pandemic: demographic changes in the general and ESRD populations. Semin Nephrol 2009; in press.
23. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9. (Pubitemid 29019345)
24. Kilhovd BK, Juutilainen A, Lehto S et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005; 25: 815-820. (Pubitemid 40463875)
25. Koschinsky T, He CJ, Mitsuhashi T et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997; 94: 6474-6479. (Pubitemid 27270709)
26. Makita Z, Bucala R, Rayfield EJ et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343: 1519-1522. (Pubitemid 24180047)
27. Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842.
28. Stirban A, Negrean M, Stratmann B et al. Benfotiamine prevents macroand microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006; 29: 2064-2071. (Pubitemid 44871188)
29. Uribarri J, Peppa M, Cai W et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003; 14: 728-731. (Pubitemid 36246017)
30. Uribarri J, Stirban A, Sander D et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 2007; 30: 2579-2582. (Pubitemid 47547799)
31. Vlassara H, Cai W, Crandall J et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002; 99: 15596-15601. (Pubitemid 35403978)
32. He CJ, Koschinsky T, Buenting C et al. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med 2001; 7: 159-168. (Pubitemid 33701987)
33. Cai W, He JC, Zhu L et al. AGE-receptor-1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am J Physiol Cell Physiol 2008; 294: C145-C152.
34. Lu C, He JC, Cai W et al. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci USA 2004; 101: 11767-11772. (Pubitemid 39099304)
35. Chen Y, Akirav EM, Chen W et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol 2008; 181: 4272-4278.
36. Hudson BI, Kalea AZ, Del Mar Arriero M et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem 2008; 283: 34457-34468.
37. Wendt T, Tanji N, Guo J et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003; 14: 1383-1395. (Pubitemid 36514678)
38. Cai W, He JC, Zhu L et al. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 2006; 103: 13801-13806. (Pubitemid 44413988)
39. Ferrucci L. The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey and plans for the future. J Gerontol A Biol Sci Med Sci 2008; 63: 1416-1419.
40. Goldberg T, Cai W, Peppa M et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004; 104: 1287-1291. (Pubitemid 39036519)
41. Woodruff S, Goodman S, Yong A et al. Control of toxic advanced glycation end products in foods: methods and implications for clinical practice. Am J Clin Nutr 2009; in press.
42. Vlassara H, Cai W, Goodman S et al. Protection against loss of innate defenses in adulthood by low AGE intake: role of anti-inflammatory AGE receptor-1. J Clin Endocrinol Metab 2009; in press.
43. Vlassara H, Cai W, Striker G et al. Different patterns of human mononuclear cell AGER1 and RAGE expression in health and disease; role of basal oxidant stress. Am J Physiol 2009; in press.
44. He CJ, Zheng F, Stitt A et al. Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. Kidney Int 2000; 58: 1931-1940. (Pubitemid 30807921)
45. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGEpeptides by renal proximal tubular cells. Diabetologia 1996; 39: 149-160. (Pubitemid 26031025)
46. Miyata T, Ueda Y, Horie K et al. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 1998; 53: 416-422. (Pubitemid 28097858)
47. Dukkipati R, Adler S, Mehrotra R. Cardiovascular implications of chronic kidney disease in older adults. Drugs Aging 2008; 25: 241-253.
48. Perkovic V, Verdon C, Ninomiya T et al. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 2008; 5: e207.
49. Ballantyne CM, Hoogeveen RC, McNeill AM et al. Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study. Int J Obes (Lond) 2008; 32(Suppl 2): S21-S24. (Pubitemid 351671298)
50. Eckel RH, Wassef M, Chait A et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation 2002; 105: e138-e143.
51. Navarro-Díaz M, Serra A, López D et al. Obesity, inflammation, and kidney disease. Kidney Int Suppl 2008; 74: S15-S18.
52. Kurella M, Chertow GM, Fried LF et al. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 2005; 16: 2127-2133. (Pubitemid 41716444)
53. Hailpern SM, Melamed ML, Cohen HW et al. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2007; 18: 2205-2213.
54. Kurella M, Chertow GM, Luan J et al. Cognitive impairment in chronic kidney disease. J Am Geriatr Soc 2004; 52: 1863-1869. (Pubitemid 41710270)
55. Fazekas G, Fazekas F, Schmidt R et al. Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment. J Neurol Sci 1995; 134: 83-88.
56. Sehgal AR, Grey SF, DeOreo PB et al. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am J Kidney Dis 1997; 30: 41-49.
57. Murray AM, Tupper DE, Knopman DS et al. Cognitive impairment in hemodialysis patients is common. Neurology 2006; 67: 216-223. (Pubitemid 44305402)
58. Martinez-Vea A, Salvadó E, Bardají A et al. Silent cerebral white matter lesions and their relationship with vascular risk factors in middle-aged predialysis patients with CKD. Am J Kidney Dis 2006; 47: 241-250. (Pubitemid 43121327)
59. Seliger SL, Gillen DL, Longstreth Jr WT et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64: 603-609. (Pubitemid 36871932)
60. Bleys J, Miller III ER, Pastor-Barriuso R et al. Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2006; 84: 880-887. (Pubitemid 44715671)
61. de Bree A, Verschuren WM, Blom HJ et al. Coronary heart disease mortality, plasma homocysteine, and B-vitamins: a prospective study. Atherosclerosis 2003; 166: 369-377. (Pubitemid 36071696)
62. Traber MG. Heart disease and single-vitamin supplementation. Am J Clin Nutr 2007; 85: 293S-299S.
63. Ward NC, Wu JH, Clarke MW et al. The effect of vitamin E on blood pressure in individuals with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Hypertens 2007; 25: 227-234. (Pubitemid 44885685)
64. Sofi F, Cesari F, Abbate R et al. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 2008; 337: a1344.
65. Roman B, Carta L, Martínez-González MA et al. Effectiveness of the Mediterranean diet in the elderly. Clin Interv Aging 2008; 3: 97-109.
66. Brownlee M, Vlassara H, Kooney A et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-1632. (Pubitemid 16095602)
67. Bolton WK, Cattran DC, Williams ME et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40. (Pubitemid 38250484)
68. Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005; 62: 1671-1681.
69. Williams ME, Bolton WK, Khalifah RG et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007; 27: 605-614.
70. Weindruch R. Aging in rodents fed restricted diets. J Am Geriatr Soc 1985; 33: 125-132. (Pubitemid 15171748)